Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
The European Journal of Health Economics · 2025
DOI: 10.1007/s10198-024-01754-3 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The European Journal of Health Economics, 2025. Verfasst von Simon van der Schans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Health-Ecore, Zeist, The Netherlands. S.van.der.schans@umcg.nl. Hauptthemen laut MEDLINE: Oligonucleotides, Spinal Muscular Atrophies of Childhood, Biological Products. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Gene Therapies.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health-Ecore, Zeist, The Netherlands. S.van.der.schans@umcg.nl.
- Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, 9173 GZ, The Netherlands. S.van.der.schans@umcg.nl.
- Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, 9173 GZ, The Netherlands.
- Asc Academics, Groningen, The Netherlands.
- Clarivate, Munich, Germany.
- Clarivate, Manchester, UK.
Förderung
- Novartis Gene Therapies
Zitieren
APA
van der Schans, S., Velikanova, R., Weidlich, D., Howells, R., Patel, A., Bischof, M., Postma, M. J., & Boersma, C. (2025). Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01754-3
Vancouver
van der Schans S, Velikanova R, Weidlich D, Howells R, Patel A, Bischof M, et al. Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. The European Journal of Health Economics. 2025. doi:10.1007/s10198-024-01754-3
BibTeX
@article{vanderSchans2025,
author = {van der Schans, Simon and Velikanova, Rimma and Weidlich, Diana and Howells, Ruth and Patel, Anish and Bischof, Matthias and Postma, Maarten J and Boersma, Cornelis},
title = {Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands},
journal = {The European Journal of Health Economics},
year = {2025},
doi = {10.1007/s10198-024-01754-3}
}
EUVIMED